BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Results Of Two New Preclinical Studies Evaluating Novel Combinations Of TH-302 With Immunotherapy, Antiangiogenic Therapy, And Radiotherapy To Be Presented At American Association for Cancer Research Annual Meeting 2014 4/4/2014 10:01:16 AM    More...
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany Initiates Phase 1 Dose Escalation Study Of TH-302 In Combination With Gemcitabine And Nab-paclitaxel (Abraxane(R)) In Pancreatic Cancer 3/27/2014 11:12:00 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Reports Fourth Quarter And Year End 2013 Financial And Operational Results 3/7/2014 9:18:40 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentations And Webcasts At Three Upcoming Investor Conferences 2/21/2014 9:12:05 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces Target Enrollment Of 620 Patients Achieved In Pivotal Phase 3 Trial Of TH-302 In Advanced Soft Tissue Sarcoma 12/30/2013 9:15:36 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Reports TH-302 Data At The 55th Annual Meeting Of American Society of Hematology 12/9/2013 11:19:39 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Oppenheimer 24th Annual Healthcare Conference 12/4/2013 10:06:04 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces New Clinical Data On TH-302 And Avastin® (Bevacizumab) In Recurrent Glioblastoma Following Bevacizumab Failure 11/22/2013 9:53:35 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces TH-302 Data to be Presented at American Society of Hematology 11/8/2013 9:13:42 AM    More...
Threshold Pharmaceuticals, Inc. (THLD) Announces Early Clinical Data for Combining TH-302 With Antiangiogenic Agents in Advanced Solid Tumors 10/21/2013 9:28:03 AM    More...
12345678910...

//-->